CL2022000115A1 - Terapia genética cardíaca con aav para la cardiomiopatía en humanos. - Google Patents

Terapia genética cardíaca con aav para la cardiomiopatía en humanos.

Info

Publication number
CL2022000115A1
CL2022000115A1 CL2022000115A CL2022000115A CL2022000115A1 CL 2022000115 A1 CL2022000115 A1 CL 2022000115A1 CL 2022000115 A CL2022000115 A CL 2022000115A CL 2022000115 A CL2022000115 A CL 2022000115A CL 2022000115 A1 CL2022000115 A1 CL 2022000115A1
Authority
CL
Chile
Prior art keywords
cardiac
humans
compositions
methods
cardiomyopathy
Prior art date
Application number
CL2022000115A
Other languages
English (en)
Inventor
Hugh Lee Sweeney
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of CL2022000115A1 publication Critical patent/CL2022000115A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22061—Caspase-8 (3.4.22.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación se relaciona con composiciones y métodos útiles en el tratamiento de afecciones cardíacas. Las composiciones y métodos divulgados se basan en terapias génicas que comprenden un vector de AAV recombinante para el suministro de dos o más transgenes en el corazón de un sujeto humano, en donde los transgenes comprenden una proteína S100A1 y un Represor de la Apoptosis cardíaca con un inhibidor apoptótico del Dominio de Reclutamiento de Caspasas (cARC). En diversas realizaciones, las composiciones y los métodos divulgados en la presente comprenden vectores que constan de secuencias de ADNc de cARC y/o S100A1 que son optimizados con codones para la expresión en humanos. En algunos aspectos, la focalización en múltiples fuentes de una o más afecciones cardíacas puede proporcionar beneficios sinérgicos durante el tratamiento.
CL2022000115A 2019-07-19 2022-01-17 Terapia genética cardíaca con aav para la cardiomiopatía en humanos. CL2022000115A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962876540P 2019-07-19 2019-07-19

Publications (1)

Publication Number Publication Date
CL2022000115A1 true CL2022000115A1 (es) 2022-10-07

Family

ID=74193792

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000115A CL2022000115A1 (es) 2019-07-19 2022-01-17 Terapia genética cardíaca con aav para la cardiomiopatía en humanos.

Country Status (16)

Country Link
US (1) US20220265858A1 (es)
EP (1) EP3999074A4 (es)
JP (1) JP2022541793A (es)
KR (1) KR20220034801A (es)
CN (1) CN114206351A (es)
AR (1) AR122289A1 (es)
AU (1) AU2020316339A1 (es)
BR (1) BR112022000898A2 (es)
CA (1) CA3142534A1 (es)
CL (1) CL2022000115A1 (es)
CO (1) CO2022001686A2 (es)
IL (1) IL289667A (es)
MX (1) MX2022000767A (es)
SG (1) SG11202112140SA (es)
TW (1) TW202117017A (es)
WO (1) WO2021016126A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022140402A1 (en) * 2020-12-23 2022-06-30 University Of Florida Research Foundation, Incorporated Increased packaging efficiency of vector for cardiac gene therapy
WO2023147304A1 (en) 2022-01-25 2023-08-03 The Trustees Of The University Of Pennsylvania Aav capsids for improved heart transduction and detargeting of liver
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
WO2024130067A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002216751A1 (en) * 2000-06-30 2002-01-14 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
WO2008054713A2 (en) * 2006-10-30 2008-05-08 Thomas Jefferson University Tissue specific gene therapy treatment
EP2295072A1 (en) * 2009-09-15 2011-03-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Use of ARC for inhibiting cell death during liver failure
EP3452101A2 (en) * 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US20200308582A1 (en) * 2017-10-12 2020-10-01 Universität Heidelberg Kcnk3-based gene therapy of cardiac arrhythmia
CN112272705A (zh) * 2018-06-08 2021-01-26 佛罗里达大学研究基金会有限公司 用于心肌病的aav心脏基因治疗

Also Published As

Publication number Publication date
WO2021016126A1 (en) 2021-01-28
EP3999074A4 (en) 2023-08-16
AU2020316339A1 (en) 2021-11-18
CO2022001686A2 (es) 2022-03-29
BR112022000898A2 (pt) 2022-06-07
CN114206351A (zh) 2022-03-18
KR20220034801A (ko) 2022-03-18
WO2021016126A8 (en) 2021-09-10
TW202117017A (zh) 2021-05-01
CA3142534A1 (en) 2021-01-28
JP2022541793A (ja) 2022-09-27
AU2020316339A2 (en) 2021-11-25
MX2022000767A (es) 2022-04-25
AR122289A1 (es) 2022-08-31
SG11202112140SA (en) 2021-11-29
IL289667A (en) 2022-03-01
EP3999074A1 (en) 2022-05-25
US20220265858A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
CL2022000115A1 (es) Terapia genética cardíaca con aav para la cardiomiopatía en humanos.
CO2020016718A2 (es) Terapia génica cardíaca con aav para cardiomiopatía
CL2021001058A1 (es) Proteínas heterodiméricas fusionadas con fc
PE20211419A1 (es) Vectores virales recombinantes y acidos nucleicos para producirlos
PE20181922A1 (es) Terapia genica para tratar la hemofilia a
CO2020010376A2 (es) Uso de vectores lentivirales que expresan el factor viii
UY37636A (es) Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1
CL2021003096A1 (es) Partículas virales modificadas y usos de estas
AR116700A1 (es) Generación de una mejor fenilalanina hidroxilasa hepática humana para el tratamiento de la fenilcetonuria severa por terapia génica de reemplazo directo en el hígado
MX2020013163A (es) Metodos para tratar trastornos linfoproliferativos malignos.
CO2021016487A2 (es) Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
ECSP20055797A (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
CL2023001876A1 (es) Proteínas de la cápside viral con especificidad para las células del tejido cardiaco
CL2022003147A1 (es) Composiciones y métodos para tratar pérdida auditiva asociada con gjb2
CO2023006811A2 (es) Mayor eficiencia del empaquetamiento de vectores para terapia génica cardíaca
CO2022006772A2 (es) Composiciones y métodos para el tratamiento de los trastornos de almacenamiento de glucógeno
BR112018006572A2 (pt) terapia de combinação racional para o tratamento de câncer
AR110947A1 (es) Tratamiento de degeneración de la retina mediante el uso de células progenitoras
EA202092654A1 (ru) Генная терапия сердца с помощью aav при кардиомиопатии
CO2018007251A2 (es) Métodos y composiciones para el tratamiento del síndrome de hunter
EA202192964A1 (ru) Комбинированная терапия
DOP2023000132A (es) Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1
ECSP23093588A (es) Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva